Comparison
Ostarine vs LGD-4033
Ostarine: lean preservation & mildness. LGD-4033: next-level size & strength.
Ostarine
Selective Androgen Receptor Modulator
LGD-4033
Selective Androgen Receptor Modulator
Effectiveness Profile
At a Glance
| Ostarine | LGD-4033 | |
|---|---|---|
| Type | SARM | SARM |
| Legal status | Research | Research |
| Half-life | ~24 hours | 24–36 hours |
| Preferred route | Oral | Oral |
| Dose frequency | once-daily | once-daily |
| Beginner dose | 10–15 mg | 5–5 mg |
| Intermediate dose | 20–25 mg | 5–10 mg |
| Advanced dose | 25–30 mg | 10–20 mg |
| Cycle length | 8–12 wks | 6–8 wks |
| Bioavailability | 85% | 90% |
| Time to peak | 3h | 2h |
| Active duration | 24h | 24h |
| Storage | Room temperature, away from light; liquid suspensions stable for months sealed | Room temperature, dry, away from light |
| PCT required | Yes | Yes |
| Ancillaries required | Yes | Yes |
| Safe for women | Yes | No |
| Anabolic / androgenic | 90 / 30 | 500 / 1 |
Verdict
Ostarine wins for minimal side effects, daily-functioning safety, and ultra-reliable muscle retention in deficit or bridge protocols. Suppression and lipid impact stay moderate at community doses, and side effect risk is tame outside fringe cases or aggressive stacks.
LGD-4033 wins for raw anabolic effect, visible scale increases, and serious strength gains without aromatization or heavy water retention. Runs closer to entry-level injectable AAS in results, though at the price of notably stronger suppression and lipid impact. LGD is the SARM of choice when size matters more than total cycle safety.
Pick A or B?
Pick Ostarine if:
- You want to preserve lean mass during a cut or contest prep, not chase bulk
- You're running your first SARM and want manageable side effects and light suppression
- Female users or those sensitive to androgenic effects need a safety-first option
- You're bridging between AAS cycles or recomping at maintenance
- Short, low-side-effect cycles with minimal recovery required are a priority
Pick LGD-4033 if:
- You value lean bulk and actual new muscle as the main outcome (not just retention)
- Strength gains and scale movement are higher priorities than lowest-possible sides
- You've outgrown ostarine's effects and want a SARM that rivals mild injectables
- Willing to run a structured mini-PCT and take HDL suppression seriously
- Cutting isn't the top goal — your focus is size, not just preservation